Due to the COVID-19 pandemic, the global Monoamine Oxidase-B market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Monoamine Oxidase-B market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Monoamine Oxidase-B landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Nonselective MAO-B inhibitors accounting for % of the Monoamine Oxidase-B global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Atypical Depression Treatment segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Monoamine Oxidase-B include Novartis, Pfizer, Validus Pharmaceuticals LLC, Eli Lilly & Company, GlaxoSmithKline, Merck & Co and Concordia Pharms, etc. In terms of revenue, the global 3 largest players have a % market share of Monoamine Oxidase-B in 2021.
This report focuses on Monoamine Oxidase-B volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Monoamine Oxidase-B market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Monoamine Oxidase-B Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Nonselective MAO-B inhibitors
Selective MAO-B inhibitors
Segment by Application
Atypical Depression Treatment
Parkinson's Disease Treatment
Other Therapy
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Novartis
Pfizer
Validus Pharmaceuticals LLC
Eli Lilly & Company
GlaxoSmithKline
Merck & Co
Concordia Pharms